POSB342 Time Until Definitive Deterioration (TUDD) in Patient Reported Outcomes (PROS) in a Phase 3 Trial for Ripretinib in 4L Patients with Gastrointestinal Stromal Tumour (GIST)
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.1109
https://www.valueinhealthjournal.com/article/S1098-3015(21)02904-1/fulltext
Section Title :
Section Order :
10648
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02904-1&doi=10.1016/j.jval.2021.11.1109